We analyzed outcomes by international geographic region in the Irbesartan in Heart Failure with Preserved systolic function trial ( I-Preserve ) , the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity ( CHARM ) - Preserved trial , the CHARM-Alternative and CHARM-Added HF-REF trials , and the Controlled Rosuvastatin Multinational Trial in HF-REF ( CORONA ) .